Zonisamide Viatris: Uses, Dosage & Side Effects
An antiepileptic medication used to treat partial (focal) seizures in adults and children aged 6 years and older
Zonisamide Viatris is an antiepileptic (anticonvulsant) medication containing the active substance zonisamide. It is used to treat epilepsy, specifically partial (focal) seizures with or without secondary generalization. In adults, it can be prescribed as monotherapy or alongside other antiepileptic drugs. In adolescents and children aged 6 years and older, it is used as add-on therapy. Zonisamide belongs to the sulfonamide class and works through multiple mechanisms including sodium channel blockade and calcium channel modulation. It requires a prescription and should be initiated and supervised by a specialist physician experienced in the management of epilepsy.
Quick Facts: Zonisamide Viatris
Key Takeaways
- Zonisamide is an antiepileptic drug approved for partial (focal) seizures with or without secondary generalization; it can be used as monotherapy in adults or as add-on therapy in adults, adolescents, and children aged 6 years and older.
- Do not take zonisamide if you are allergic to sulfonamide drugs, as it belongs to the sulfonamide class and can cause serious allergic reactions including Stevens-Johnson syndrome and potentially fatal blood disorders.
- Zonisamide can reduce sweating and increase the risk of overheating (hyperthermia), particularly in children and in hot weather; adequate hydration and avoidance of excessive heat exposure are essential during treatment.
- Common side effects include drowsiness, dizziness, appetite loss, and weight loss; most side effects occur during the first month and tend to improve with continued treatment.
- Never stop taking zonisamide suddenly, as this may trigger seizures; doses must always be reduced gradually under medical supervision.
What Is Zonisamide Viatris and What Is It Used For?
Zonisamide Viatris contains the active substance zonisamide, a benzisoxazole derivative that was first developed in Japan in the 1970s and has been widely used internationally since its approval in the European Union. It is classified as a third-generation antiepileptic drug (AED) and is approved for the treatment of epilepsy, specifically partial (focal) seizures. Partial seizures originate in one area of the brain and may remain localized (simple or complex partial seizures) or spread to involve the entire brain, a phenomenon known as secondary generalization.
The precise mechanism of action of zonisamide is multifaceted and distinguishes it from many other antiepileptic drugs that act primarily through a single pathway. Zonisamide exerts its anticonvulsant effects through several complementary mechanisms. It blocks voltage-gated sodium channels, which reduces the rapid, repetitive neuronal firing that underlies seizure activity. It also blocks T-type calcium channels, which are involved in thalamocortical circuitry and play a role in seizure generation. Additionally, zonisamide modulates both GABAergic (inhibitory) and glutamatergic (excitatory) neurotransmission, further contributing to its anticonvulsant properties. It also has weak carbonic anhydrase inhibitory activity, which contributes to some of its side effects such as kidney stone formation and metabolic acidosis.
From a pharmacokinetic perspective, zonisamide is well absorbed after oral administration, with a bioavailability approaching 100%. It reaches peak plasma concentrations within 2 to 5 hours after dosing. One of its most notable pharmacokinetic features is its exceptionally long half-life of approximately 63 hours in adults when not co-administered with enzyme-inducing drugs. This long half-life allows for once-daily dosing in many patients, which can improve treatment adherence. Zonisamide is primarily metabolized in the liver by the cytochrome P450 enzyme CYP3A4, and its metabolites are excreted through the kidneys.
Zonisamide Viatris is indicated in the following clinical scenarios:
- Monotherapy in adults: Treatment of partial (focal) seizures with or without secondary generalization in adults with newly diagnosed epilepsy.
- Adjunctive therapy in adults: Treatment of partial seizures with or without secondary generalization in adults whose seizures are not adequately controlled with one or more other antiepileptic drugs.
- Adjunctive therapy in children and adolescents: Treatment of partial seizures with or without secondary generalization in adolescents and children aged 6 years and older, used alongside other antiepileptic medications.
It is important to note that zonisamide is not recommended for children under 6 years of age, as the benefit-risk balance has not been established for this age group. The medication is available as hard capsules in strengths of 25 mg, 50 mg, and 100 mg, allowing for flexible dose titration. Zonisamide Viatris is a generic version of the originator product and contains the same active substance in the same pharmaceutical form and strength.
Zonisamide Viatris is a generic medication that has been demonstrated to be bioequivalent to the originator product. This means it contains the same active substance (zonisamide), in the same strength, and delivers the same blood levels as the reference product. Generic medicines undergo rigorous regulatory review to ensure they meet the same quality, safety, and efficacy standards as their branded counterparts. Other brands of zonisamide, such as Zonisamide 1A Farma, contain the same active ingredient and can be expected to have similar clinical effects.
What Should You Know Before Taking Zonisamide Viatris?
Contraindications
There are specific situations where Zonisamide Viatris must not be used. Understanding these absolute contraindications is critical for patient safety.
- Sulfonamide allergy: Do not take zonisamide if you have a known hypersensitivity to zonisamide or to any other sulfonamide drug. The sulfonamide class includes certain antibiotics (e.g., sulfamethoxazole), thiazide diuretics (e.g., hydrochlorothiazide), and sulfonylurea antidiabetic medications (e.g., glibenclamide). Cross-reactivity between these groups can occur, and taking zonisamide with a known sulfonamide allergy can trigger serious, potentially life-threatening allergic reactions.
- Hypersensitivity to excipients: Do not take this medicine if you are allergic to any of the other ingredients listed in the composition, including gelatin (present in the capsule shell) or sodium lauryl sulfate.
Warnings and Precautions
Zonisamide belongs to the sulfonamide group of medicines, which can cause severe allergic reactions, serious skin rashes (including Stevens-Johnson syndrome and toxic epidermal necrolysis), and blood disorders that in very rare cases can be fatal. Contact your doctor immediately if you develop a skin rash, difficulty breathing, facial swelling, swollen glands, unexplained bruising, fever, or sore throat during treatment.
Before starting and during treatment with Zonisamide Viatris, you should discuss the following conditions and risk factors with your doctor:
- Suicidal thoughts: A small number of people treated with antiepileptic drugs, including zonisamide, have experienced thoughts of self-harm or suicide. If you experience such thoughts at any time, contact your doctor immediately. This risk applies to all patients taking antiepileptic medications and requires vigilant monitoring, particularly at the start of treatment or when doses are changed.
- Reduced sweating and overheating (oligohidrosis and hyperthermia): Zonisamide can reduce sweating, which impairs the body's ability to regulate temperature. This can lead to dangerous overheating (hyperthermia), particularly in hot weather, during vigorous physical activity, or in children. Drink plenty of water and stay cool, especially in warm environments. Children are at greatest risk, and parents should monitor for signs of overheating including high body temperature with little or no sweating, rapid heartbeat, rapid breathing, muscle cramps, and confusion.
- Kidney stones: Zonisamide increases the risk of developing kidney stones due to its carbonic anhydrase inhibitory activity. Patients with a previous history of kidney stones are at even greater risk. Reduce this risk by drinking adequate amounts of water daily. Symptoms of kidney stones include sudden back or abdominal pain, pain during urination, or blood in the urine. Contact your doctor immediately if you experience any of these symptoms.
- Metabolic acidosis: Zonisamide can cause elevated blood ammonia levels (hyperammonemia), particularly when taken with other medications that increase ammonia levels such as valproate, or in patients with hereditary urea cycle disorders or liver problems. It can also decrease blood bicarbonate levels, leading to metabolic acidosis. Symptoms include headache, drowsiness, shortness of breath, and loss of appetite. Your doctor may need to check your blood bicarbonate and ammonia levels regularly.
- Liver problems: If you have liver disease, your dose of zonisamide may need to be adjusted, and your liver function should be monitored during treatment.
- Kidney problems: If you have impaired kidney function, your dose may need to be adjusted, as zonisamide and its metabolites are primarily eliminated through the kidneys.
- Elderly patients: Older adults may require dose adjustments and are at increased risk of allergic reactions, serious skin rashes, swelling of the feet and legs, and itching during zonisamide treatment.
- Eye problems: If you have or have had glaucoma (increased pressure in the eye), inform your doctor, as zonisamide has been associated with acute myopia and secondary angle-closure glaucoma in rare cases. Seek immediate medical attention if you develop eye pain, redness, or sudden changes in vision.
- Weight loss: Zonisamide commonly causes decreased appetite and weight loss. Patients who are underweight or have lost significant weight should discuss this with their doctor. Weight should be monitored throughout treatment, particularly in children, where adequate growth and weight gain are essential.
Use in Children and Adolescents
Zonisamide is approved for adjunctive therapy in children aged 6 years and older. It is not recommended for children under 6 years of age. Children are at particular risk of certain side effects associated with zonisamide, and specific precautions are essential.
Zonisamide can significantly reduce sweating in children, leading to a dangerous rise in body temperature. If left untreated, this can lead to brain damage and death. Children are most at risk, especially in hot weather. When your child is taking zonisamide: keep them cool, especially in hot weather; avoid vigorous exercise in heat; ensure they drink plenty of cold water; and do not give them carbonic anhydrase inhibitors (such as topiramate or acetazolamide) or anticholinergic drugs (such as oxybutynin) simultaneously unless directed by a doctor. If your child's skin feels very hot with little or no sweating, if they become confused, develop muscle cramps, or their heart rate or breathing becomes rapid, move them to a cool shaded area, sponge their skin with cool water, give them cold water to drink, and seek medical attention immediately.
Additional considerations for children include regular weight monitoring, as zonisamide can impair weight gain. The medication is not recommended for children who are underweight or have poor appetite, and should be used with caution in children weighing less than 20 kg. Blood bicarbonate levels and kidney function should be checked regularly, and the risk of kidney stones should be minimized by ensuring adequate fluid intake.
Pregnancy and Breastfeeding
Women of childbearing potential must use adequate contraception during treatment with Zonisamide Viatris and for one month after discontinuation. If you are planning to become pregnant, speak to your doctor before stopping contraception and before becoming pregnant, so that alternative treatments can be discussed. If you are already pregnant or think you may be pregnant, contact your doctor immediately. Do not stop taking the medication without medical advice, as sudden discontinuation can trigger seizures that may pose risks to both mother and baby.
Research has demonstrated an increased risk of birth defects (congenital malformations) in infants born to women taking antiepileptic drugs during pregnancy. One study found that infants born to mothers using zonisamide during pregnancy were smaller than expected for their gestational age compared with those born to mothers treated with lamotrigine monotherapy. The risk of malformations or neurodevelopmental problems following prenatal exposure to zonisamide is not fully characterized. Zonisamide should only be used during pregnancy if the doctor determines that the potential benefits clearly outweigh the risks, and only at the lowest effective dose.
Breastfeeding is not recommended during treatment with Zonisamide Viatris and for one month after the last dose. Zonisamide is excreted in human breast milk, and the potential effects on the nursing infant have not been adequately studied.
There are no clinical data on the effects of zonisamide on human fertility. Animal studies have shown changes in fertility parameters, and the clinical significance of these findings is uncertain.
Driving and Operating Machinery
Zonisamide may affect your ability to concentrate and react, and may cause drowsiness, particularly at the beginning of treatment and when your dose is increased. Exercise particular caution when driving or operating machinery if zonisamide affects you in this way. You should not drive or operate dangerous machinery until you know how zonisamide affects you personally. Discuss with your doctor whether your occupation requires any special precautions.
How Does Zonisamide Viatris Interact with Other Drugs?
Although zonisamide has a relatively manageable drug interaction profile compared to some older antiepileptic drugs, several clinically important interactions exist that can affect both the efficacy and safety of treatment. Always inform your doctor, pharmacist, or nurse about all prescription and over-the-counter medications, herbal remedies, vitamins, and dietary supplements you are taking or plan to take.
Drugs That Affect Zonisamide Levels
Zonisamide is primarily metabolized by the liver enzyme CYP3A4. Drugs that induce (speed up) this enzyme can significantly reduce zonisamide blood levels, potentially decreasing its seizure-controlling effectiveness. Your doctor may need to increase your zonisamide dose if you are also taking any of these medications.
| Interacting Drug | Effect on Zonisamide | Clinical Advice |
|---|---|---|
| Phenytoin | Potent CYP3A4 inducer; can reduce zonisamide half-life from 63 hours to approximately 27 hours, significantly lowering blood levels | Dose of zonisamide may need to be increased. Monitor seizure control and zonisamide levels if phenytoin is started, stopped, or dose-changed. |
| Carbamazepine | CYP3A4 inducer; reduces zonisamide half-life to approximately 38 hours, lowering blood levels | Higher zonisamide doses may be needed. Monitor clinical response and adjust accordingly. |
| Phenobarbital | CYP3A4 inducer; reduces zonisamide exposure, potentially impairing seizure control | May require zonisamide dose adjustment. Close monitoring of seizure frequency is advised. |
| Rifampicin | Potent broad-spectrum enzyme inducer; can substantially reduce zonisamide levels | If rifampicin must be used (e.g., for tuberculosis), significant zonisamide dose increases may be necessary. Monitor closely. |
Drugs That Zonisamide May Affect
Zonisamide may potentially increase the blood levels of certain medications, which could lead to enhanced effects or increased side effects of those drugs.
| Affected Drug | Potential Effect | Clinical Advice |
|---|---|---|
| Digoxin | Zonisamide may increase digoxin blood levels, increasing the risk of digoxin toxicity (nausea, visual disturbances, arrhythmias) | Monitor digoxin levels when starting or adjusting zonisamide. Dose reduction of digoxin may be necessary. |
| Quinidine | Zonisamide may increase quinidine blood levels, raising the risk of cardiac side effects | Monitor quinidine levels and cardiac function. Dose adjustment of quinidine may be required. |
Important Combination Warnings
In adults, zonisamide should be used with caution alongside topiramate or acetazolamide, as both drugs (like zonisamide) inhibit carbonic anhydrase, and combining them substantially increases the risk of kidney stones. This combination is not recommended in children. If you are taking any of these medications, discuss the risks with your doctor and ensure adequate fluid intake.
- Valproate (valproic acid, sodium valproate): Co-administration with valproate can increase the risk of hyperammonemia (elevated blood ammonia levels), which may affect brain function and cause confusion, drowsiness, and in severe cases, encephalopathy. Inform your doctor immediately if you feel unusually sleepy or confused.
- Anticholinergic medications: Drugs with anticholinergic properties (e.g., clomipramine, hydroxyzine, diphenhydramine, haloperidol, imipramine, oxybutynin) can exacerbate zonisamide's effect on sweating and increase the risk of overheating, particularly in children.
Zonisamide Viatris can be taken with or without food. Food does not significantly affect its absorption. The capsules should be swallowed whole with water – do not chew or crush them.
What Is the Correct Dosage of Zonisamide Viatris?
Always take Zonisamide Viatris exactly as your doctor has instructed. Do not change your dose without consulting your doctor or pharmacist. Zonisamide capsules must be swallowed whole with water – do not chew or open the capsules. The medication can be taken with or without food, once or twice daily as prescribed.
Adults
Monotherapy (Zonisamide alone)
- Starting dose: 100 mg taken once daily
- Dose increases: May be increased by up to 100 mg at intervals of two weeks
- Recommended maintenance dose: 300 mg once daily
Adjunctive Therapy (with other antiepileptic drugs)
- Starting dose: 50 mg daily, divided into two equal doses of 25 mg (morning and evening)
- Dose increases: May be increased by up to 100 mg at intervals of one to two weeks
- Recommended maintenance dose: 300 mg to 500 mg daily
Some patients may respond to lower doses. The dose should be increased more slowly in patients who experience side effects, are elderly, or have kidney or liver problems. When switching from adjunctive therapy to monotherapy, the concomitant antiepileptic drugs should be withdrawn gradually under medical supervision.
Children (6 to 11 years) and Adolescents (12 to 17 years)
Zonisamide dosing in children and adolescents is based on body weight. The minimum body weight for treatment is 20 kg.
Pediatric Dosing (weight-based)
- Starting dose: 1 mg per kg body weight, taken once daily
- Dose increases: May be increased by 1 mg per kg at intervals of one to two weeks
- Target dose: 6 to 8 mg per kg daily for children up to 55 kg, or 300 to 500 mg daily for children over 55 kg (whichever dose is lower), taken once daily
Example: A child weighing 25 kg should take 25 mg once daily during the first week, then increase by 25 mg per week until a daily dose of 150 to 200 mg is reached.
Elderly Patients
Elderly patients may require dose adjustments due to age-related changes in kidney and liver function. Older adults are also at increased risk of certain side effects, including allergic reactions, serious skin rashes, swelling of the feet and legs, and itching. Treatment should be initiated at the lowest recommended dose, and dose increases should be made more cautiously. Close monitoring is essential throughout treatment.
Missed Dose
If you forget to take a dose of Zonisamide Viatris, simply take your next dose at the usual time. Do not take a double dose to make up for a missed dose. If you regularly forget doses, consider setting a daily alarm or using a pill organizer to help maintain consistent dosing, as maintaining steady blood levels is important for effective seizure control.
Overdose
If you or someone else has taken too much Zonisamide Viatris, contact your doctor, hospital emergency department, or poison control center immediately. Symptoms of overdose may include drowsiness, loss of consciousness, nausea, stomach pain, muscle spasms, involuntary eye movements (nystagmus), weakness, slow heart rate, reduced breathing, and impaired kidney function. Do not drive if you have taken more than your prescribed dose.
Stopping Treatment
Zonisamide Viatris is intended for long-term treatment of epilepsy. Do not reduce your dose or stop taking the medication unless your doctor advises you to do so. If your doctor decides to discontinue your treatment, the dose will be reduced gradually over a period of weeks to minimize the risk of breakthrough seizures or status epilepticus (prolonged seizure activity). Abrupt withdrawal of any antiepileptic medication can be dangerous and should be avoided.
What Are the Side Effects of Zonisamide Viatris?
Like all medicines, Zonisamide Viatris can cause side effects, although not everybody gets them. Because zonisamide belongs to the sulfonamide group of medicines, it carries a risk of serious allergic reactions, severe skin rashes, and blood disorders that in very rare cases can be fatal.
Contact your doctor or seek emergency medical help immediately if you experience any of the following: difficulty breathing, swelling of the face, lips or tongue, or severe skin rash (signs of a serious allergic reaction); signs of overheating – high body temperature with little or no sweating, rapid heartbeat, rapid breathing, muscle cramps, and confusion; thoughts of harming yourself or suicide; muscle pain or weakness (possible signs of abnormal muscle breakdown that can lead to kidney damage); sudden pain in the back or abdomen, pain during urination, or blood in the urine (possible kidney stones); or eye pain, blurred vision, or other vision problems while taking zonisamide.
In children aged 6 to 17 years, the side effects were generally the same as in adults, with the following additional effects reported: pneumonia and dehydration, decreased sweating (common), abnormal liver enzymes (uncommon), ear infection, sore throat, sinusitis, upper respiratory tract infection, cough, nosebleeds, runny nose, abdominal pain, vomiting, rash, eczema, and fever.
Very Common
May affect more than 1 in 10 people
- Agitation, irritability, confusion, depression
- Poor muscle coordination (ataxia), dizziness, memory problems, drowsiness
- Double vision (diplopia)
- Decreased appetite
- Reduced blood bicarbonate levels (metabolic acidosis)
Common
May affect up to 1 in 10 people
- Insomnia, unusual or strange thoughts, anxiety, emotional instability
- Slow thinking, impaired concentration, speech difficulties, abnormal skin sensations (numbness, tingling), tremor, involuntary eye movements (nystagmus)
- Kidney stones
- Skin rash, itching, allergic reactions, fever, fatigue, flu-like symptoms, hair loss
- Easy bruising (ecchymosis)
- Weight loss, nausea, indigestion, abdominal pain, diarrhea, constipation, vomiting
- Swelling of the feet and legs (peripheral edema)
- Mood swings
- Elevated blood creatinine, elevated liver enzymes
Uncommon
May affect up to 1 in 100 people
- Anger, aggression, suicidal thoughts, suicide attempt
- Gallbladder inflammation (cholecystitis), gallstones
- Urinary tract stones
- Lung infection/inflammation, urinary tract infection
- Low potassium levels (hypokalemia), seizures/convulsions
- Breathing difficulties, hallucinations
- Abnormal urine test results
Very Rare
May affect up to 1 in 10,000 people
- Memory loss (amnesia), coma, neuroleptic malignant syndrome (inability to move, sweating, fever, incontinence), prolonged or repeated seizures (status epilepticus)
- Shortness of breath, pneumonia
- Pancreatitis (severe pain in the abdomen or back)
- Liver problems, kidney failure
- Severe skin rashes or skin peeling (Stevens-Johnson syndrome, toxic epidermal necrolysis)
- Abnormal muscle breakdown (rhabdomyolysis) which may lead to kidney damage
- Swollen glands, blood disorders (reduced blood cell counts leading to increased infection risk, pallor, tiredness, fever, or easy bruising)
- Decreased sweating (oligohidrosis), heat stroke
- Glaucoma (increased pressure in the eye causing eye pain, blurred or decreased vision)
- Elevated creatine phosphokinase or urea in blood tests
- Abnormal liver function test results
Reporting suspected side effects after the medicine has been authorized is important. It allows continued monitoring of the benefit-risk balance of the medicine. Healthcare professionals and patients are encouraged to report suspected adverse reactions through their national pharmacovigilance system. You can also report side effects to your doctor or pharmacist.
How Should You Store Zonisamide Viatris?
Proper storage of medication is important to maintain its effectiveness and safety throughout its shelf life. Follow these guidelines for storing Zonisamide Viatris:
- Keep out of reach: Store this medicine out of the sight and reach of children at all times. Use a locked medicine cabinet if possible.
- Expiry date: Do not use this medicine after the expiry date stated on the blister and carton after "EXP." The expiry date refers to the last day of the stated month.
- Storage conditions: This medicine does not require any special storage conditions. Store at room temperature, away from excessive heat, moisture, and direct light.
- Inspect before use: Do not use the medicine if you notice that the capsules, the blister pack, or the carton are damaged, or if you see any signs that the medicine has deteriorated. Return the package to your pharmacy.
- Disposal: Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment.
What Does Zonisamide Viatris Contain?
Understanding the composition of your medication is important, particularly if you have known allergies or sensitivities to specific substances. Below is a detailed breakdown of what each strength of Zonisamide Viatris contains.
Active Ingredient
The active substance in all strengths is zonisamide. Each capsule contains either 25 mg, 50 mg, or 100 mg of zonisamide, depending on the prescribed strength.
Inactive Ingredients (Excipients)
| Component | 25 mg | 50 mg | 100 mg |
|---|---|---|---|
| Capsule contents | Microcrystalline cellulose, hydrogenated vegetable oil, sodium lauryl sulfate | Microcrystalline cellulose, hydrogenated vegetable oil, sodium lauryl sulfate | Microcrystalline cellulose, hydrogenated vegetable oil, sodium lauryl sulfate |
| Capsule shell | Gelatin, titanium dioxide (E171) | Gelatin, titanium dioxide (E171) | Gelatin, titanium dioxide (E171) |
| Printing ink | Shellac, black iron oxide (E172), potassium hydroxide | Shellac, red iron oxide (E172) | Shellac, black iron oxide (E172), sodium lauryl sulfate |
| Appearance | White body and cap, marked "Z 25" in black | White body and cap, marked "Z 50" in red | White body and cap, marked "Z 100" in black |
All capsules contain white to almost white powder. The product is available in blister packs of various sizes (14, 28, 56 capsules for 25 mg and 50 mg; 28, 56, 98, 196 capsules for 100 mg), as well as perforated unit-dose blister packs. Not all pack sizes may be marketed in all countries.
Zonisamide Viatris contains less than 1 mmol (23 mg) sodium per capsule, meaning it is essentially sodium-free. This is relevant for patients on a sodium-restricted diet.
The marketing authorization holder is Viatris Limited, based in Dublin, Ireland. The medicine is manufactured by Noucor Health, S.A. in Barcelona, Spain.
Frequently Asked Questions About Zonisamide Viatris
Zonisamide Viatris is a generic version of zonisamide. It contains the same active ingredient (zonisamide) in the same strength and pharmaceutical form (hard capsules) as the originator product. Generic medicines must demonstrate bioequivalence to the reference product, meaning they deliver the same amount of active substance into the bloodstream at the same rate. Regulatory authorities such as the European Medicines Agency (EMA) require generic medicines to meet the same quality, safety, and efficacy standards as their branded equivalents. In practice, switching between generic versions of the same medication under medical supervision is considered safe and effective.
It is generally advisable to avoid or limit alcohol consumption while taking zonisamide. Alcohol can enhance the central nervous system depressant effects of zonisamide, including drowsiness, dizziness, and impaired concentration, which increases the risk of accidents and falls. Alcohol can also lower the seizure threshold in people with epilepsy, potentially triggering seizures. If you have questions about alcohol use during your treatment, discuss them with your doctor.
Zonisamide has a long half-life (approximately 63 hours), which means it takes several days to reach steady blood levels after starting or changing a dose. It can take 2 to 4 weeks at a stable dose to see the full effect on seizure control. Because the dose is typically increased gradually over several weeks to the target maintenance dose, it may take 2 to 3 months before you reach the optimal therapeutic dose. Do not be discouraged if you do not notice an immediate improvement – it is important to follow your doctor's titration schedule and not to increase the dose more quickly than recommended.
Most common side effects of zonisamide are mild and tend to improve during the first few weeks of treatment. If side effects are bothersome but not severe, discuss them with your doctor, who may be able to adjust your dose or the speed of dose increases. Never stop taking zonisamide suddenly on your own, as this can trigger seizures. For serious side effects – such as severe skin rash, signs of allergic reaction, thoughts of self-harm, signs of overheating, or symptoms of kidney stones – seek immediate medical attention. Your doctor will decide whether it is safe to continue treatment.
Zonisamide is officially approved only for the treatment of epilepsy (specifically partial seizures). However, some doctors may prescribe it "off-label" for other conditions based on clinical evidence. Research has explored zonisamide's potential use in migraine prevention, essential tremor, neuropathic pain, obesity, and as adjunctive therapy in Parkinson's disease. In Japan, zonisamide is approved as an adjunctive treatment for Parkinson's disease. Any off-label use should only be undertaken under close medical supervision and after a thorough discussion of potential benefits and risks with your doctor.
Yes, zonisamide is intended for long-term use and has been prescribed continuously for many years in clinical practice. Long-term safety data are available from extensive post-marketing surveillance and clinical studies. However, long-term use requires regular medical monitoring. Your doctor should periodically check kidney function, blood bicarbonate levels, liver function, and your weight. Kidney stone risk remains throughout treatment, so adequate hydration is important. Report any new symptoms to your doctor promptly. With appropriate monitoring and follow-up, most patients can take zonisamide safely over extended periods.
References
- 1 European Medicines Agency (EMA). Zonisamide – Summary of Product Characteristics. Last updated 2025. Available at: ema.europa.eu
- 2 International League Against Epilepsy (ILAE). Updated Classification of Seizures and Epilepsies (2017, revised 2022). Epilepsia. Available at: ilae.org
- 3 National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults. NICE guideline [NG217]. Updated 2024. Available at: nice.org.uk
- 4 British National Formulary (BNF). Zonisamide monograph. Updated 2025. Available at: bnf.nice.org.uk
- 5 World Health Organization (WHO). Model List of Essential Medicines, 23rd list (2023). Available at: who.int
- 6 Brodie MJ, et al. Zonisamide: its pharmacology, efficacy and safety in clinical trials. Acta Neurol Scand. 2012;126(Suppl 194):19–28. DOI: 10.1111/ane.12016
- 7 Baulac M, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2012;11(7):579–588.
- 8 Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004;13(Suppl 1):S5–S9.
- 9 Helmstaedter C, Witt JA. The effects of levetiracetam and zonisamide on cognition. Expert Rev Neurother. 2020;20(3):221–229.
- 10 Marson AG, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1375–1386.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with expertise in neurology, clinical pharmacology, and epilepsy management.
All content is reviewed according to international guidelines from the ILAE (International League Against Epilepsy), NICE, EMA, and WHO. Our editorial process follows the GRADE evidence framework, ensuring the highest standard of medical accuracy.
iMedic operates with no commercial funding or pharmaceutical company sponsorship. Our content is produced independently to ensure unbiased, evidence-based medical information for all readers.